Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy
暂无分享,去创建一个
D. Felsher | G. Delsol | T. al Saati | F. Meggetto | S. Giuriato | E. Bousquet | N. Faumont | M. Foisseau | A. Bibonne | M. Moreau | Marianne Foisseau | Emilie Bousquet | Anne Bibonne
[1] C. Fletcher,et al. Inflammatory Myofibroblastic Tumor: Comparison of Clinicopathologic, Histologic, and Immunohistochemical Features Including ALK Expression in Atypical and Aggressive Cases , 2007, The American journal of surgical pathology.
[2] G. Delsol,et al. TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins. , 2007, European journal of cancer.
[3] Peter G. Schultz,et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK , 2007, Proceedings of the National Academy of Sciences.
[4] B. Ruggeri,et al. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. , 2006, Blood.
[5] Rongshi Li,et al. Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. , 2006, Journal of medicinal chemistry.
[6] R. Taulli,et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. , 2006, Blood.
[7] P. Włodarski,et al. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3 , 2005, Laboratory Investigation.
[8] K. Pulford,et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. , 2004, Cellular and molecular life sciences : CMLS.
[9] E. Campo,et al. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells , 2004, Oncogene.
[10] C. Shachaf,et al. Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. , 2004, Seminars in cancer biology.
[11] F. Behm,et al. ALK-positive anaplastic large cell lymphoma with leukemic peripheral blood involvement is a clinicopathologic entity with an unfavorable prognosis. Report of three cases and review of the literature. , 2003, American journal of clinical pathology.
[12] Dean W. Felsher,et al. Cancer revoked: oncogenes as therapeutic targets , 2003, Nature Reviews Cancer.
[13] C. Sawyers. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. , 2002, Cancer cell.
[14] K. Pulford,et al. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. , 1999, Blood.
[15] S. Pileri,et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. , 1998, The American journal of pathology.
[16] M. Gossen,et al. Co-regulation of two gene activities by tetracycline via a bidirectional promoter. , 1995, Nucleic acids research.
[17] S. Ōmura,et al. Treatment of Philadelphia‐chromosome‐positive human leukemia in scid mouse model with herbimycin A, bcr‐abl tyrosine kinase activity inhibitor , 1995, International journal of cancer.
[18] M. Kurosawa,et al. In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. , 1994, Leukemia research.
[19] S. Kajigaya,et al. Herbimycin A, an inhibitor of tyrosine kinase, prolongs survival of mice inoculated with myeloid leukemia C1 cells with high expression of v-abl tyrosine kinase. , 1992, Cancer research.
[20] M. Gossen,et al. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[21] A. Hannah. Kinases as drug discovery targets in hematologic malignancies. , 2005, Current molecular medicine.
[22] K. Pulford,et al. Model of inhibition of the NPM-ALK kinase activity by herbimycin A. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.